CYP19A1 and neoplasm: Accordingly, it has been evidenced how in the broad spectrum of biological actions performed by Losartan as a classical RAS antagonist, it assumes its capability to inhibit aromatase activity and the consequent local estrogen production as an important stimulatory component of tumor growth and progression.